Teva's CGRP mi­graine drug aces PhI­II while ri­vals pile up at the FDA fin­ish line

Pos­i­tive late-stage da­ta are start­ing to pile up in the CGRP mi­graine drug cat­e­go­ry, like­ly sig­nal­ing a sud­den in­flux of new drugs with re­mark­ably sim­i­lar …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER